Evidence map›Paper›PMID 36867316›Full record

ArticleInvestigational new drugs2023

Phase 1 study to determine the safety and dosing of autologous PBMCs modified to present HPV16 antigens (SQZ-PBMC-HPV) in HLA-A*02+ patients with HPV16+ solid tumors.

Antonio Jimeno, Joaquina Baranda, Wade T Iams, Jong Chul Park, Monica Mita, Michael S Gordon, Matthew Taylor, Neesha Dhani, Alexis D Leal, Prakash Neupane and 14 more

Open access · hybridAbstract readClinical Trial, Phase I
PubMed Full text at PMC Publisher
In one paragraph

Article in Investigational new drugs, 2023. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 4 papers.

0numbers the graph read from it
0cells of the map it votes in
4citing papers in PubMed
1.4field-weighted citation impact, top 17% of its field
1 · What the graph read from it

What it found

Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.

The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.

2 · The registry

The trial behind it

Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.

Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.

3 · Its place in the literature

Who cites it

4 citing papers in PubMed, 6 citations in OpenAlex.

  1. Review
  2. The Rise of Mechanobiology for Advanced Cell Engineering and Manufacturing.Advanced materials (Deerfield Beach, Fla.) · 2025
    Review
  3. Review
  4. Article
4 · The record

Corrections and comments

PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.

5 · Who and what money

Authors and funding

24 authors at 13 institutions in 3 countries.

Antonio JimenoUniversity of Colorado Comprehensive Cancer Center, 12801 East 17th Avenue, Room L18-8101B, Aurora, CO, 80045, USA. Antonio.Jimeno@cuanschutz.edu.
Joaquina BarandaUniversity of Kansas Cancer Center, Fairway, KS, USA.
Wade T IamsDivision of Hematology/Oncology, Department of Medicine, Vanderbilt-Ingram Cancer Center, Nashville, TN, USA.
Jong Chul ParkMassachusetts General Hospital, Boston, MA, USA.
Monica MitaCedars-Sinai Medical Center, Los Angeles, CA, USA.
Michael S GordonPinnacle Oncology Hematology, Arizona Center for Cancer Care, HonorHealth Research Institute Clinical Trials Program, Virginia G. Piper Cancer Center, Scottsdale, AZ, USA.
Matthew TaylorProvidence Cancer Institute, Portland, OR, USA.
Neesha DhaniUniversity Health Network Princess Margaret Cancer Centre, Toronto, Canada.
Alexis D LealUniversity of Colorado Comprehensive Cancer Center, 12801 East 17th Avenue, Room L18-8101B, Aurora, CO, 80045, USA.
Prakash NeupaneUniversity of Kansas Cancer Center, Fairway, KS, USA.
Cathy EngDivision of Hematology/Oncology, Department of Medicine, Vanderbilt-Ingram Cancer Center, Nashville, TN, USA.
Oladapo YekuMassachusetts General Hospital, Boston, MA, USA.
Alain MitaCedars-Sinai Medical Center, Los Angeles, CA, USA.
Justin C MoserPinnacle Oncology Hematology, Arizona Center for Cancer Care, HonorHealth Research Institute Clinical Trials Program, Virginia G. Piper Cancer Center, Scottsdale, AZ, USA.
Marcus ButlerUniversity Health Network Princess Margaret Cancer Centre, Toronto, Canada.
Scott M LoughheadSQZ Biotechnologies, Watertown, MA, USA.
Julia JenningsSQZ Biotechnologies, Watertown, MA, USA.
Nathan R MiselisSQZ Biotechnologies, Watertown, MA, USA.
Rui-Ru JiSQZ Biotechnologies, Watertown, MA, USA.
Nitya NairHoffmann-La Roche, Basel, Switzerland.
Martin KornackerHoffmann-La Roche, Basel, Switzerland.
Ricardo F ZwirtesSQZ Biotechnologies, Watertown, MA, USA.
Howard BernsteinSQZ Biotechnologies, Watertown, MA, USA.
Armon ShareiSQZ Biotechnologies, Watertown, MA, USA.
SQZ Biotech (United States) · USCedars-Sinai Medical Center · USMassachusetts General Hospital · USRoche (Switzerland) · CHThe University of Kansas Cancer Center · USUniversity of Colorado Cancer Center · USHonorHealth · USPinnacle Oncology Hematology · USPrincess Margaret Cancer Centre · CAProvidence Portland Medical Center · USUniversity Health Network · CAVanderbilt-Ingram Cancer CenterVanderbilt University · US

Funding

Vanderbilt Clinical Oncology Research Career Development ProgramK12CA090625 · NCI · VANDERBILT UNIVERSITY MEDICAL CENTER · PI Debra L. Friedman, Paula Jill Hurley · 2001 to 2026
$16.9M
NCI NIH HHS K12 CA090625
6 · The paper itself

Abstract

We conducted a dose escalation Phase 1 study of autologous PBMCs loaded by microfluidic squeezing (Cell Squeeze

Indexed as

NeoplasmsOncogene Proteins, ViralPapillomavirus InfectionsHLA-A AntigensHuman papillomavirus 16HumansLeukocytes, MononuclearPapillomavirus E7 ProteinsHLA-A AntigensOncogene Proteins, ViralPapillomavirus E7 ProteinsAntigen presenting cellCancer vaccineCellular therapyHPV16Immunotherapy

Identifiers

PMID36867316
PMCPMC10140074
OpenAlexW4323036146

What OpenQuestion holds

Textmetadata
LicenceCC BY
Read underepoch 390

Registered trials

None linked

Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.